DiaMedica Therapeutics Doses First Patients in Phase 2 Fetal Growth Restriction Trial

Phase 2Positive

AI Analysis

Summary

DiaMedica Therapeutics has dosed the first patients in a Phase 2 trial for fetal growth restriction. The trial represents a key milestone for the company's development program in this indication.

Clinical Trial Data

Phase

Phase 2

Importance:5/10

Sentiment:

0.50

clinical trialphase 2fetal growth restrictionpatient dosing

Related Companies

$DMAC

Read the original article

Published by yahoo_finance on June 23, 2026 1:26 PM

Read Original